236 related articles for article (PubMed ID: 36485086)
1. Management of marginal zone lymphomas.
Merli M; Arcaini L
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):676-687. PubMed ID: 36485086
[TBL] [Abstract][Full Text] [Related]
2. Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients.
Morigi A; Argnani L; Lolli G; Broccoli A; Pellegrini C; Nanni L; Stefoni V; Coppola PE; Carella M; Casadei B; Sabattini E; Cavo M; Zinzani PL
Hematol Oncol; 2020 Oct; 38(4):487-492. PubMed ID: 32594531
[TBL] [Abstract][Full Text] [Related]
3. Bendamustine and rituximab as frontline therapy in extranodal marginal zone lymphoma: a single-institution experience.
Logothetis CN; Horvat NP; Kurian T; Bello C; Chavez J; Isenalumhe L; Shah B; Sokol L; Saeed H; Pinilla J; Gaballa S
Oncol Res; 2024; 32(6):1031-1036. PubMed ID: 38827319
[TBL] [Abstract][Full Text] [Related]
4. State-of-the-art therapeutics: marginal-zone lymphoma.
Bertoni F; Zucca E
J Clin Oncol; 2005 Sep; 23(26):6415-20. PubMed ID: 16155028
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trial.
Grunenberg A; Kaiser LM; Woelfle S; Schmelzle B; Viardot A; Möller P; Barth TFE; Muche R; Dreyhaupt J; Raderer M; Kiesewetter B; Buske C
BMC Cancer; 2021 Jun; 21(1):749. PubMed ID: 34187401
[TBL] [Abstract][Full Text] [Related]
6. Front-line management of indolent non-Hodgkin lymphoma in Australia. Part 2: mantle cell lymphoma and marginal zone lymphoma.
Cheah CY; Opat S; Trotman J; Marlton P
Intern Med J; 2019 Sep; 49(9):1070-1080. PubMed ID: 30816618
[TBL] [Abstract][Full Text] [Related]
7. CD5 expression in marginal zone lymphoma predicts differential response to rituximab or bendamustine/rituximab.
Hsu A; Kurt H; Zayac AS; Olszewski AJ
Leuk Lymphoma; 2022 Jan; 63(1):31-42. PubMed ID: 34467833
[TBL] [Abstract][Full Text] [Related]
8. Marginal Zone Lymphoma: State-of-the-Art Treatment.
Sindel A; Al-Juhaishi T; Yazbeck V
Curr Treat Options Oncol; 2019 Dec; 20(12):90. PubMed ID: 31807935
[TBL] [Abstract][Full Text] [Related]
9. Bone marrow histology in marginal zone B-cell lymphomas: correlation with clinical parameters and flow cytometry in 120 patients.
Boveri E; Arcaini L; Merli M; Passamonti F; Rizzi S; Vanelli L; Rumi E; Rattotti S; Lucioni M; Picone C; Castello A; Pascutto C; Magrini U; Lazzarino M; Paulli M
Ann Oncol; 2009 Jan; 20(1):129-36. PubMed ID: 18718888
[TBL] [Abstract][Full Text] [Related]
10. Enhancing prognostication and personalizing treatment of extranodal marginal zone lymphoma.
Alderuccio JP; Lossos IS
Expert Rev Hematol; 2023 May; 16(5):333-348. PubMed ID: 37086394
[TBL] [Abstract][Full Text] [Related]
11. Medical history, lifestyle, family history, and occupational risk factors for marginal zone lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project.
Bracci PM; Benavente Y; Turner JJ; Paltiel O; Slager SL; Vajdic CM; Norman AD; Cerhan JR; Chiu BC; Becker N; Cocco P; Dogan A; Nieters A; Holly EA; Kane EV; Smedby KE; Maynadié M; Spinelli JJ; Roman E; Glimelius B; Wang SS; Sampson JN; Morton LM; de Sanjosé S
J Natl Cancer Inst Monogr; 2014 Aug; 2014(48):52-65. PubMed ID: 25174026
[TBL] [Abstract][Full Text] [Related]
12. Marginal zone lymphoma: old, new, targeted, and epigenetic therapies.
Joshi M; Sheikh H; Abbi K; Long S; Sharma K; Tulchinsky M; Epner E
Ther Adv Hematol; 2012 Oct; 3(5):275-90. PubMed ID: 23616915
[TBL] [Abstract][Full Text] [Related]
13. Results of Upfront Therapy for Marginal Zone Lymphoma.
Ortega JL; Cabanillas F; Rivera N; Tirado-Gomez M; Hallman D; Pardo WI; Bruno M
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):879-883. PubMed ID: 29042174
[TBL] [Abstract][Full Text] [Related]
14. Rituximab Monotherapy or in Combination with Bendamustine Is Not Inferior to Rituximab-CHOP Regimen in the Treatment of Patients with Splenic Marginal Zone Lymphoma in the Real Life.
Mulas O; Caocci G; Dessì D; Mantovani D; Moi G; Cabras MG; La Nasa G
Acta Haematol; 2021; 144(3):322-326. PubMed ID: 32892194
[TBL] [Abstract][Full Text] [Related]
15. Management of Marginal Zone Lymphoma: A Canadian Perspective.
Peters A; Keating MM; Nikonova A; Doucette S; Prica A
Curr Oncol; 2023 Feb; 30(2):1745-1759. PubMed ID: 36826096
[TBL] [Abstract][Full Text] [Related]
16. The bendamustine plus rituximab regimen is active against primary nodal marginal zone B-cell lymphoma.
Laribi K; Tempescul A; Ghnaya H; Denizon N; Besançon A; Anghel A; Farhi J; Truong C; Lemaire P; Poulain S; Bolle D; Ianotto JC; Baugier de Materre A
Hematol Oncol; 2017 Dec; 35(4):536-541. PubMed ID: 27443419
[TBL] [Abstract][Full Text] [Related]
17. The many faces of marginal zone lymphoma.
Zinzani PL
Hematology Am Soc Hematol Educ Program; 2012; 2012():426-32. PubMed ID: 23233614
[TBL] [Abstract][Full Text] [Related]
18. Contemporary management of nodal and primary splenic marginal zone lymphoma.
Leslie LA; Feldman TA; McNeill A; Timberg M; Iida H; Goy AH
Expert Rev Hematol; 2019 Dec; 12(12):1011-1022. PubMed ID: 31619091
[No Abstract] [Full Text] [Related]
19. Current Treatments in Marginal Zone Lymphoma.
Alderuccio JP; Kahl BS
Oncology (Williston Park); 2022 Apr; 36(4):206-215. PubMed ID: 35436062
[TBL] [Abstract][Full Text] [Related]
20. Primary nodal marginal zone lymphomas of splenic and MALT type.
Campo E; Miquel R; Krenacs L; Sorbara L; Raffeld M; Jaffe ES
Am J Surg Pathol; 1999 Jan; 23(1):59-68. PubMed ID: 9888704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
